FAA Marijuana Aviation Rules: Pilots, Controllers, and Cannabis Policy

Executive Summary

The Federal Aviation Administration is considering significant revisions to its marijuana policies for pilots, air traffic controllers, and other safety-sensitive aviation personnel as of August 2026. The proposed changes come as 38 states have legalized medical cannabis and 24 have approved adult-use programs, creating a widening gap between federal aviation safety regulations and state-level cannabis normalization. The FAA currently maintains a zero-tolerance policy for marijuana use among all aviation certificate holders under 14 CFR § 67.307, regardless of state law or medical authorization. The agency's review follows mounting pressure from pilot advocacy groups, aviation unions, and congressional representatives who argue that blanket prohibition fails to distinguish between impairment and trace metabolite detection that can persist weeks after use. Any policy shift would require balancing public safety imperatives with evolving scientific understanding of cannabis pharmacokinetics, detection technology limitations, and the practical reality that qualified aviators in legal-use states face career-ending consequences for off-duty consumption that would not impair flight operations.

Why This Matters

The FAA's marijuana policy directly affects the careers of approximately 734,000 certificated pilots, 14,500 air traffic controllers, and tens of thousands of aircraft mechanics, dispatchers, and other safety-sensitive aviation workers nationwide. The current zero-tolerance framework creates a binary choice: aviation careers or legal cannabis use, even for medical conditions in states where physicians recommend it. The economic stakes extend beyond individual livelihoods. The U.S. aviation industry contributes $1.8 trillion annually to the national economy and supports 10.6 million jobs according to the FAA's most recent economic impact analysis. A chronic pilot shortage that began in 2021 has intensified, with regional airlines operating at 15-20% below optimal staffing levels as of mid-2026. Industry analysts estimate the shortage could reach 12,000 pilots by 2028 if current trends continue. Aviation medical examiners report that qualified pilot candidates increasingly decline to pursue aviation careers due to state-legal cannabis use, particularly military veterans using medical marijuana for service-related conditions. The Air Line Pilots Association has documented 47 cases since 2023 where experienced pilots lost medical certificates after testing positive for THC metabolites despite no evidence of impairment or on-duty use. The policy also affects aircraft accident investigation protocols. The National Transportation Safety Board conducts post-accident toxicology on all fatal aviation accidents, and positive THC results—even from consumption days or weeks prior—create legal liability questions for operators, insurers, and estates regardless of whether cannabis contributed to the accident. Patient advocacy groups emphasize that current rules effectively bar medical cannabis patients from aviation careers, even in states where cannabis is the only effective treatment for conditions like epilepsy, PTSD, or chronic pain that would not otherwise disqualify someone from holding a medical certificate.

Background and History

The FAA's marijuana prohibition predates the Controlled Substances Act and has remained essentially unchanged for six decades despite dramatic shifts in state law, medical research, and public policy.

Pre-1970: Early Aviation Drug Policy

The Federal Aviation Act of 1958 granted the FAA broad authority to establish medical standards for airmen certificates but did not specifically address marijuana. Early Federal Air Surgeon guidance from the 1960s classified cannabis alongside alcohol and other intoxicants as incompatible with safe flight operations, relying on limited pharmacological data from that era.

1970-1990: Controlled Substances Framework

The Controlled Substances Act of 1970 classified marijuana as a Schedule I substance under 21 U.S.C. § 812, defining it as having no accepted medical use and high abuse potential. The FAA incorporated this classification into aviation medical standards through 14 CFR Part 67, which established that "substance dependence" or "substance abuse" disqualified applicants from medical certificates. In 1987, following several high-profile accidents involving drug use, Congress passed the Omnibus Drug Act requiring random drug testing for safety-sensitive transportation workers. The Department of Transportation implemented 49 CFR Part 40 in 1989, establishing standardized testing protocols for aviation, rail, maritime, and other modes. The regulations set a 50 ng/mL cutoff for THC metabolites in urine screening, with 15 ng/mL confirmation threshold—levels that detect use days or weeks prior rather than current impairment.

1996-2012: State Medical Marijuana Programs Begin

California became the first state to legalize medical cannabis through Proposition 215 in 1996. The FAA immediately clarified that state medical marijuana authorizations provided no exception to federal aviation regulations. In a 1997 legal interpretation, the agency stated that marijuana use "for any reason" was disqualifying, and pilots who used cannabis under state medical programs would lose their medical certificates. By 2012, 18 states had enacted medical marijuana programs, but the FAA maintained its absolute prohibition. The agency's position was that as long as marijuana remained Schedule I under federal law, aviation safety standards could not accommodate any use.

2012-2020: Adult-Use Legalization and Pilot Advocacy

Colorado and Washington became the first states to legalize adult-use cannabis in 2012. The FAA issued a reminder to airmen in 2013 emphasizing that state legalization did not change federal aviation medical standards. The agency noted that pilots could be denied medical certificates for marijuana use even if legal under state law. The Aircraft Owners and Pilots Association began advocating for policy review in 2015, arguing that detection of inactive THC metabolites weeks after use did not indicate impairment or safety risk. The organization commissioned research on cannabis pharmacokinetics and submitted comments to the FAA requesting science-based impairment standards rather than zero-tolerance metabolite detection. In 2018, the Agriculture Improvement Act (2018 Farm Bill) legalized hemp and hemp-derived cannabinoids containing less than 0.3% delta-9 THC. The FAA issued guidance warning pilots that CBD products could contain sufficient THC to trigger positive drug tests, and that use of any cannabis-derived product remained grounds for certificate denial.

2021-2024: Congressional Pressure and Policy Review

The FAA Reauthorization Act of 2023 included a provision directing the agency to study alternatives to zero-tolerance marijuana policies for pilots and air traffic controllers. The legislation required a report to Congress by December 2024 examining detection technology, impairment research, international aviation standards, and potential policy modifications. In June 2024, the Department of Justice published a Notice of Proposed Rulemaking to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act. While the rescheduling would acknowledge accepted medical use, the FAA clarified that Schedule III status would not automatically change aviation medical standards, which independently prohibit use of any impairing substance.

2025-2026: Formal Policy Review

The FAA submitted its congressionally mandated report in January 2025, concluding that current drug testing technology cannot reliably distinguish recent use from consumption days or weeks prior, and that no validated roadside-style impairment test exists for cannabis. The report recommended continued prohibition pending development of better detection methods, but acknowledged that blanket disqualification of medical cannabis patients raised equity concerns. In March 2026, the National Academies of Sciences, Engineering, and Medicine released a comprehensive review of cannabis and transportation safety commissioned by the Department of Transportation. The report found that while acute cannabis intoxication impairs psychomotor skills relevant to safety-sensitive tasks, THC metabolite presence alone does not predict impairment or crash risk. The study recommended that transportation agencies develop performance-based impairment standards rather than relying solely on metabolite detection. The August 2026 announcement that the FAA is weighing new marijuana rules follows this research and reflects growing recognition that zero-tolerance policies may be unsustainable as cannabis normalization continues.

Key Players

Federal Aviation Administration

The FAA holds statutory authority under 49 U.S.C. § 44703 to establish medical standards for airmen certificates. The agency's Aerospace Medical Certification Division within the Office of Aerospace Medicine administers the medical certification program through a network of approximately 3,500 Aviation Medical Examiners nationwide. Administrator Michael Whitaker has indicated the agency is reviewing marijuana policies but emphasized that any changes must maintain the highest safety standards and cannot conflict with federal law.

Department of Transportation

DOT establishes drug testing requirements for all transportation modes under 49 CFR Part 40. The Office of Drug and Alcohol Policy and Compliance oversees implementation and maintains the prohibited substances list. Any FAA policy change regarding marijuana would require coordination with DOT's broader drug testing framework affecting 12.5 million safety-sensitive workers across aviation, trucking, rail, transit, maritime, and pipeline sectors.

Air Line Pilots Association

ALPA represents 78,000 pilots at 41 airlines in the United States and Canada. The union has advocated for science-based impairment testing since 2019, arguing that current metabolite detection punishes off-duty legal behavior without correlation to safety risk. ALPA supports development of cognitive performance testing that could identify actual impairment from any cause rather than detecting trace substances from prior use.

Aircraft Owners and Pilots Association

AOPA represents 320,000 general aviation pilots and aircraft owners. The organization has submitted multiple petitions and comment letters requesting FAA policy review, particularly regarding medical cannabis use for conditions like chronic pain, PTSD, and seizure disorders. AOPA commissioned independent research on cannabis detection windows and impairment correlation, which it has shared with the agency.

National Air Traffic Controllers Association

NATCA represents 20,000 air traffic controllers and aviation safety professionals. The union has taken a more cautious position than pilot groups, emphasizing that controllers work in safety-critical positions where any impairment risk is unacceptable. NATCA supports continued prohibition until definitive real-time impairment testing becomes available.

Regional Airline Association

RAA represents regional airlines facing acute pilot shortages. The organization has noted that marijuana policies may discourage qualified candidates, particularly military veterans, from pursuing aviation careers. RAA supports policy review but emphasizes that any changes must not compromise safety or create public confidence issues.

Aviation Medical Examiners

The approximately 3,500 physicians authorized to conduct FAA medical examinations implement current policy at the individual airman level. Many AMEs report increasing numbers of applicants who have used state-legal cannabis and must be denied certification under current rules, even when the examiner believes the individual poses no safety risk.

National Organization for the Reform of Marijuana Laws

NORML has advocated for ending blanket marijuana prohibitions in employment, including aviation, arguing that off-duty legal use should not disqualify individuals from careers. The organization supports performance-based impairment standards and has submitted comments to the FAA requesting policy modernization.

Legal and Regulatory Framework

The FAA's marijuana prohibition rests on multiple overlapping federal statutes and regulations that create a complex legal framework resistant to simple policy changes. The foundational authority is 49 U.S.C. § 44703(a), which grants the FAA power to issue airman certificates and establish medical standards. The statute requires that certificate holders be "physically able" to perform their duties safely. Medical certification standards appear in 14 CFR Part 67, which establishes three classes of medical certificates with varying requirements. Section 67.307 specifically addresses substance dependence and abuse, stating that a diagnosis of substance dependence or substance abuse within the previous two years is disqualifying for all classes. The regulation defines substance as including marijuana regardless of state law. The testing framework derives from 49 CFR Part 40, which DOT established under the Omnibus Transportation Employee Testing Act of 1991. Part 40 requires random drug testing of safety-sensitive aviation employees at a minimum 25% annual rate for controlled substances including marijuana. The regulation specifies urine testing with 50 ng/mL initial cutoff and 15 ng/mL confirmation threshold for THC metabolites. Anti-drug provisions specific to aviation appear in 14 CFR § 120.11, which prohibits individuals from performing safety-sensitive functions while having a prohibited drug in their system. The regulation does not require proof of impairment—mere presence of metabolites constitutes a violation. The Controlled Substances Act classification of marijuana as Schedule I under 21 U.S.C. § 812 provides the federal law foundation for FAA policy. Schedule I designation means marijuana has no accepted medical use under federal law, which the FAA has historically cited as justification for not recognizing state medical cannabis programs. The 2018 Farm Bill at 7 U.S.C. § 1639o legalized hemp containing less than 0.3% delta-9 THC but did not exempt hemp-derived cannabinoids from FAA prohibition. The agency maintains that any cannabis-derived substance poses certification risk due to potential THC content and lack of regulatory oversight. International obligations under the Convention on International Civil Aviation (Chicago Convention) require the United States to maintain medical standards for pilots operating internationally. Annex 1 to the Convention establishes international medical standards, though it does not specifically address marijuana policy, leaving implementation to individual states. The Administrative Procedure Act at 5 U.S.C. § 553 governs how the FAA could change marijuana policies. Any substantive rule change would require notice-and-comment rulemaking, including publication of a Notice of Proposed Rulemaking in the Federal Register, a public comment period of at least 60 days, and consideration of comments before issuing a final rule. Legal precedent from the U.S. Court of Appeals has consistently upheld FAA medical certificate denials based on marijuana use. In multiple cases, courts have deferred to the agency's expertise on aviation safety and rejected arguments that state medical marijuana laws create exceptions to federal aviation standards.

Current Policy Implementation

Under existing FAA protocols, any marijuana use—medical or recreational, on-duty or off-duty, recent or remote—results in medical certificate denial or revocation for pilots and disqualification for air traffic controllers. Aviation Medical Examiners ask all applicants during medical examinations whether they use marijuana or other controlled substances. Applicants who disclose cannabis use cannot be issued a medical certificate. Those who falsely answer "no" commit a federal offense under 18 U.S.C. § 1001 for making false statements to a federal agency. Random drug testing protocols under 49 CFR Part 40 require employers to test 25% of safety-sensitive employees annually for controlled substances. Airlines, air traffic control facilities, and other aviation employers use DOT-certified laboratories that follow strict chain-of-custody procedures. A positive test result triggers immediate removal from safety-sensitive duties. When a pilot or air traffic controller tests positive for THC metabolites, the Medical Review Officer contacts the individual to determine if there is a legitimate medical explanation. Because marijuana has no federally recognized medical use, state medical cannabis authorizations are not considered legitimate explanations. The MRO reports the test as positive to the employer and the FAA. The FAA maintains the National Driver Register and receives reports of positive drug tests. A positive marijuana test results in revocation of existing medical certificates and denial of future applications. Pilots who test positive must undergo substance abuse evaluation and complete rehabilitation requirements before they can apply for certificate reinstatement, typically requiring a minimum two-year waiting period. For medical certificate applications, the FAA requires applicants to report all visits to health care professionals within the previous three years. If medical records indicate marijuana use or a cannabis recommendation from a physician, the application is denied. Applicants who omit this information and are later discovered face certificate revocation and potential federal prosecution for false statements. The agency maintains a special issuance process under 14 CFR § 67.401 for conditions that are normally disqualifying but may be acceptable with additional documentation. However, current marijuana use is not eligible for special issuance. Only applicants who have completely abstained from cannabis for a minimum of two years and completed substance abuse treatment can apply for special issuance consideration. Air traffic controllers face similar prohibitions under FAA Order 3910.1C, which establishes drug testing requirements for the Air Traffic Organization. Controllers are subject to pre-employment testing, random testing, reasonable suspicion testing, and post-accident testing. A single positive marijuana test results in termination.

Scientific and Medical Considerations

The central scientific challenge in aviation marijuana policy is that current testing technology detects inactive metabolites that persist long after psychoactive effects have dissipated, creating a mismatch between detection and impairment. THC, the primary psychoactive compound in cannabis, is rapidly metabolized in the body. Peak impairment occurs within 30 minutes to 2 hours after inhalation, with effects typically subsiding within 3-4 hours according to research published in Clinical Chemistry. However, THC metabolites—particularly THC-COOH—are fat-soluble and can be detected in urine for days or weeks after use depending on frequency, dose, and individual metabolism. Standard workplace drug tests measure THC-COOH at cutoff levels of 50 ng/mL for screening and 15 ng/mL for confirmation. These thresholds were established in the 1980s based on available technology and policy considerations, not on correlation with impairment. Research published in the Journal of Analytical Toxicology has demonstrated that regular cannabis users can test positive at these levels 30 days or more after last use, long after any psychoactive effects. Blood testing for active THC provides a narrower detection window of hours rather than weeks, but establishing impairment thresholds remains controversial. Several states have enacted per se drugged driving laws with THC blood concentration limits of 5 ng/mL or less, but the National Highway Traffic Safety Administration has noted that THC blood levels correlate poorly with impairment compared to alcohol blood concentration. Cognitive performance testing offers a potential alternative approach. Computerized tests measuring reaction time, attention, and psychomotor coordination can detect impairment from any cause—fatigue, medication, illness, or substance use. The FAA already uses cognitive testing in some contexts, such as evaluating pilots recovering from neurological conditions. However, establishing baseline performance and accounting for individual variation presents implementation challenges. The medical cannabis question adds complexity. Patients using cannabis for conditions like epilepsy, PTSD, chronic pain, or chemotherapy side effects may benefit therapeutically without experiencing significant impairment, particularly with CBD-dominant formulations or low-dose THC regimens. Current FAA policy makes no distinction between high-dose recreational use and low-dose medical use, or between THC-dominant and CBD-dominant products. Emerging cannabinoids further complicate the landscape. Delta-8 THC, THC-O, THCA, and other hemp-derived compounds occupy legal gray areas and may or may not trigger positive drug tests depending on metabolite cross-reactivity. The FAA has warned pilots that any cannabinoid use poses certification risk, but enforcement remains inconsistent.

International Comparisons

Aviation authorities in other countries with legal cannabis markets have adopted varying approaches, though most maintain prohibition for safety-sensitive aviation personnel. Transport Canada maintains a zero-tolerance policy for pilots and air traffic controllers despite nationwide cannabis legalization in 2018. Canadian aviation regulations under CAR 404.04 prohibit acting as a crew member within eight hours of cannabis use, but the agency recommends much longer abstention periods—28 days for occasional users and three months for regular users—based on detection window research. The European Union Aviation Safety Agency defers to individual member states on medical certification standards. Most European countries prohibit marijuana use for pilots regardless of national cannabis laws. Germany, which has a medical cannabis program, denies pilot medical certificates to cannabis users even with physician authorization. Australia's Civil Aviation Safety Authority prohibits pilots from flying within eight hours of cannabis use under Civil Aviation Order 48.1, similar to alcohol rules. However, CASA acknowledges that eight hours may be insufficient for complete elimination and recommends longer abstention periods based on usage patterns. New Zealand's Civil Aviation Authority takes a strict approach, stating that any cannabis use is incompatible with holding a medical certificate. The agency does not recognize the country's medical cannabis program as providing an exception to aviation medical standards. No major aviation authority has implemented a policy allowing active cannabis use by pilots or air traffic controllers, even in countries with legal recreational markets. The international consensus remains that cannabis use poses unacceptable safety risks for safety-sensitive aviation functions, though debate continues about detection methods and abstention periods.

What Experts Say

Aviation safety experts, medical professionals, and policy analysts have offered divergent views on marijuana policy reform, reflecting genuine uncertainty about how to balance safety, science, and evolving social norms. The Aerospace Medical Association, the professional organization for aviation medical examiners, has stated that current evidence does not support allowing any cannabis use by individuals in safety-sensitive aviation positions. According to the organization's position paper, the lack of reliable real-time impairment testing and the safety-critical nature of aviation operations justify continued prohibition until better science emerges. The National Academies report on cannabis and transportation safety concluded that THC impairs cognitive and psychomotor performance in ways relevant to safety-sensitive tasks, but that metabolite testing alone is insufficient to determine impairment status. The report recommended that transportation agencies develop performance-based standards while acknowledging the technical challenges in implementation. Dr. Michael Kosnett, a clinical toxicologist who has studied workplace drug testing, has noted that urine testing for THC metabolites is poorly suited for safety-sensitive positions because it cannot distinguish between recent use and consumption days or weeks prior. According to his research, alternative matrices like oral fluid provide shorter detection windows more closely aligned with impairment periods. The Drug and Alcohol Testing Industry Association has emphasized that current testing technology serves as a deterrent rather than an impairment measure. The organization notes that employers in safety-sensitive industries rely on testing to identify individuals who use prohibited substances, not to prove intoxication at a specific time. Aviation safety consultant and former NTSB investigator John Goglia has argued that the FAA should focus on actual impairment rather than off-duty behavior that poses no safety risk. According to his analysis, the agency has tools to address impaired performance through check rides, line checks, and performance monitoring without blanket prohibition of legal substances used responsibly during off-duty time. The American Civil Liberties Union has contended that zero-tolerance policies for legal substances constitute employment discrimination and disproportionately affect medical patients who depend on cannabis for legitimate health conditions. The organization has called for reasonable accommodation of off-duty legal use in all industries including aviation. Pilot and aerospace medicine researcher Dr. Quay Snyder has stated that any policy change must account for individual variation in cannabis metabolism and the potential for impairment to persist beyond subjective effects. According to his research, some individuals may experience subtle cognitive deficits for 24 hours or more after use, even when they feel sober.

Potential Policy Scenarios

The FAA faces several potential paths forward, each with distinct safety, legal, and practical implications.

Maintain Status Quo

The agency could retain current zero-tolerance policy, arguing that safety imperatives and federal law require continued prohibition regardless of state legalization trends. This approach avoids legal and regulatory complexity but faces growing criticism as unsustainable given cannabis normalization and pilot shortage pressures.

Extended Abstention Periods

The FAA could adopt the Canadian model of allowing cannabis use but requiring extended abstention before safety-sensitive duties—potentially 30 to 90 days depending on usage frequency. This would require switching from metabolite testing to performance-based evaluation or honor-system reporting, raising enforcement challenges.

Medical Cannabis Exception

The agency could create a special issuance pathway for medical cannabis patients using low-dose, CBD-dominant formulations for specific conditions, requiring regular monitoring and performance testing. This would require distinguishing medical from recreational use and establishing acceptable formulations and dosing protocols.

Performance-Based Testing

The FAA could shift from metabolite detection to cognitive performance testing, establishing baseline measurements for each pilot and requiring pre-flight testing to ensure performance meets standards. This approach would detect impairment from any cause but would require significant infrastructure investment and validation research.

Risk-Based Categorization

The agency could differentiate between certificate types, potentially allowing limited cannabis use for private pilots while maintaining strict prohibition for commercial pilots and air traffic controllers. This would create a tiered system based on safety criticality but could face legal challenges regarding equal treatment.

Federal Law Contingency

The FAA could announce that policy review is contingent on marijuana rescheduling or federal legalization, maintaining current prohibition until Congress changes the Controlled Substances Act. This defers the decision but provides no timeline for resolution.

What's Next

The FAA's policy review timeline remains uncertain, but several key decision points will shape the outcome over the next 12-24 months. The Department of Justice's marijuana rescheduling process continues with an administrative law judge hearing scheduled for December 2026. If marijuana moves from Schedule I to Schedule III, the FAA would need to determine whether rescheduling affects aviation medical standards. The agency has indicated that Schedule III status alone would not automatically permit use, but it could provide legal foundation for policy modifications. The FAA Reauthorization Act expires in September 2027, and Congress is expected to begin reauthorization hearings in early 2027. Marijuana policy for pilots and air traffic controllers will likely be addressed in the legislation, potentially through mandatory policy review requirements, research funding, or specific directives to the agency. The National Academies is conducting follow-up research on cannabis impairment detection technology, with results expected in mid-2027. This research will examine oral fluid testing, performance-based assessment tools, and other alternatives to urine metabolite testing that could provide more accurate impairment correlation. Several aviation industry groups plan to submit formal petitions for rulemaking to the FAA in fall 2026, requesting specific policy changes. These petitions would trigger formal agency response requirements under the Administrative Procedure Act, potentially initiating the rulemaking process. State-level developments will continue to pressure federal policy. As of August 2026, six additional states have marijuana legalization measures on the November 2026 ballot. If these pass, 30 states representing 75% of the U.S. population would have legal adult-use cannabis, intensifying the federal-state policy gap. The pilot shortage is projected to worsen through 2028, potentially creating economic pressure for policy reform. Regional airlines have indicated that current hiring challenges may force route reductions and service cuts to smaller communities, which could generate congressional attention to barriers preventing qualified candidates from entering aviation careers. International developments may also influence U.S. policy. The International Civil Aviation Organization is conducting a global review of cannabis policies for aviation personnel, with a report expected in 2027. While ICAO standards are not binding, they influence national regulations and could provide cover for policy changes if international consensus emerges.

Market and Industry Implications

Any FAA marijuana policy change would ripple through the aviation industry with significant economic and operational consequences. Airlines face complex cost-benefit calculations. Relaxed policies could expand the pilot candidate pool and ease hiring challenges, potentially saving regional carriers millions in training costs and recruitment expenses. However, carriers also face liability concerns—if an accident involves a pilot who used cannabis legally under revised FAA rules, plaintiffs' attorneys would likely argue that policy change enabled the accident regardless of whether cannabis contributed. Insurance markets would need to adjust. Aviation insurers currently rely on zero-tolerance drug policies as a risk mitigation factor in underwriting. Policy changes could affect premium calculations, coverage terms, and claims handling. Insurers might require additional testing protocols or performance monitoring as conditions of coverage. Aviation medical examiners would need extensive retraining on new standards, particularly if the FAA adopts a special issuance process for medical cannabis users. The approximately 3,500 AMEs nationwide would need guidance on acceptable formulations, dosing protocols, monitoring requirements, and documentation standards. Drug testing companies would see business model disruption. The industry currently conducts approximately 2.5 million DOT-mandated aviation drug tests annually at an average cost of $45 per test, generating over $110 million in annual revenue. A shift to performance-based testing or alternative matrices would require new equipment, training, and procedures. Flight schools and pilot training programs would need to update curricula and student guidance. Many programs currently emphasize that any marijuana use is career-ending for aspiring pilots. Policy changes would require nuanced education about legal use, abstention requirements, and career risks. Labor unions would face internal divisions. While pilot unions have generally supported policy review, air traffic controller unions have been more cautious. Any policy change would require extensive labor-management negotiation on implementation, testing protocols, and disciplinary procedures.

Further Reading

• FAA Aviation Medical Certification Standards - 14 CFR Part 67 - https://www.ecfr.gov/current/title-14/chapter-I/subchapter-D/part-67
• DOT Drug Testing Procedures - 49 CFR Part 40 - https://www.ecfr.gov/current/title-49/subtitle-A/part-40
• FAA Drug and Alcohol Testing Program - 14 CFR Part 120 - https://www.ecfr.gov/current/title-14/chapter-I/subchapter-F/part-120
• Controlled Substances Act - 21 U.S.C. § 812 - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13-subchapI-partB-sec812.pdf
• National Academies Report: Cannabis and Transportation Safety (2026) - https://www.nationalacademies.org
• FAA Congressionally Mandated Report on Marijuana Policy (January 2025) - https://www.faa.gov
• Air Line Pilots Association Position Paper on Cannabis Testing - https://www.alpa.org
• Aircraft Owners and Pilots Association Medical Certification Resources - https://www.aopa.org/go-fly/medical-resources
• Transport Canada Civil Aviation Medicine: Cannabis and Aviation - https://tc.canada.ca/en/aviation/civil-aviation-medicine
• European Union Aviation Safety Agency Medical Requirements - https://www.easa.europa.eu/en/domains/medical